MX2020003339A - Arn guía de cpf1 modificado. - Google Patents
Arn guía de cpf1 modificado.Info
- Publication number
- MX2020003339A MX2020003339A MX2020003339A MX2020003339A MX2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A
- Authority
- MX
- Mexico
- Prior art keywords
- arn
- nucleic acid
- provides
- cpf1 guide
- modified cpf1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567123P | 2017-10-02 | 2017-10-02 | |
| US201862617138P | 2018-01-12 | 2018-01-12 | |
| US201862697327P | 2018-07-12 | 2018-07-12 | |
| PCT/US2018/054027 WO2019070762A1 (en) | 2017-10-02 | 2018-10-02 | RNA GUIDE CPF1 MODIFIED |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003339A true MX2020003339A (es) | 2020-11-06 |
Family
ID=64184173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003339A MX2020003339A (es) | 2017-10-02 | 2018-10-02 | Arn guía de cpf1 modificado. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606823B2 (enExample) |
| EP (1) | EP3692154A1 (enExample) |
| JP (2) | JP2020537540A (enExample) |
| KR (2) | KR102907044B1 (enExample) |
| CN (2) | CN111770994B (enExample) |
| AU (2) | AU2018345683B2 (enExample) |
| BR (1) | BR112020006601A2 (enExample) |
| CA (1) | CA3077189A1 (enExample) |
| IL (2) | IL273595B2 (enExample) |
| MX (1) | MX2020003339A (enExample) |
| SG (1) | SG11202003083PA (enExample) |
| WO (1) | WO2019070762A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201616590D0 (en) | 2016-09-29 | 2016-11-16 | Oxford Nanopore Technologies Limited | Method |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| KR102907044B1 (ko) | 2017-10-02 | 2026-01-02 | 진에딧 인코포레이티드 | 변형된 cpf1 가이드 rna |
| US11268092B2 (en) | 2018-01-12 | 2022-03-08 | GenEdit, Inc. | Structure-engineered guide RNA |
| IL277234B2 (en) * | 2018-03-14 | 2026-03-01 | Editas Medicine Inc | Systems and methods for treating hemoglobin diseases |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| GB201913997D0 (en) * | 2019-09-27 | 2019-11-13 | Oxford Nanopore Tech Ltd | Method |
| CN114929250A (zh) * | 2019-12-18 | 2022-08-19 | 爱迪塔斯医药公司 | 用于疗法的经工程化的细胞 |
| CN113234701B (zh) * | 2020-10-20 | 2022-08-16 | 珠海舒桐医疗科技有限公司 | 一种Cpf1蛋白及基因编辑系统 |
| WO2022125329A1 (en) * | 2020-12-07 | 2022-06-16 | Inscripta, Inc. | gRNA STABILIZATION IN NUCLEIC ACID-GUIDED NICKASE EDITING |
| US20250325698A1 (en) * | 2022-04-13 | 2025-10-23 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| US20240167029A1 (en) * | 2022-06-27 | 2024-05-23 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ，インコーポレーテッド | Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法 |
| WO2025212120A1 (en) * | 2024-04-05 | 2025-10-09 | Arbor Biotechnologies, Inc. | Chemical modifications of guide rnas for crispr nucleases |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US11306328B2 (en) | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| WO2016022866A1 (en) | 2014-08-07 | 2016-02-11 | Agilent Technologies, Inc. | Cis-blocked guide rna |
| WO2016028843A2 (en) | 2014-08-19 | 2016-02-25 | President And Fellows Of Harvard College | Rna-guided systems for probing and mapping of nucleic acids |
| WO2016065364A1 (en) | 2014-10-24 | 2016-04-28 | Life Technologies Corporation | Compositions and methods for enhancing homologous recombination |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| US10920221B2 (en) | 2015-05-13 | 2021-02-16 | President And Fellows Of Harvard College | Methods of making and using guide RNA for use with Cas9 systems |
| US10526590B2 (en) | 2015-08-31 | 2020-01-07 | Agilent Technologies, Inc. | Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination |
| US20180237800A1 (en) | 2015-09-21 | 2018-08-23 | The Regents Of The University Of California | Compositions and methods for target nucleic acid modification |
| WO2017064546A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
| EP3350327B1 (en) * | 2015-10-23 | 2018-09-26 | Caribou Biosciences, Inc. | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids |
| WO2017099494A1 (ko) * | 2015-12-08 | 2017-06-15 | 기초과학연구원 | Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도 |
| WO2017180711A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Grna fusion molecules, gene editing systems, and methods of use thereof |
| KR102370675B1 (ko) | 2016-04-29 | 2022-03-04 | 바스프 플랜트 사이언스 컴퍼니 게엠베하 | 표적 핵산의 변형을 위한 개선된 방법 |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| JP2019517261A (ja) | 2016-06-01 | 2019-06-24 | カーヴェーエス ザート ソシエタス・ヨーロピアＫｗｓ Ｓａａｔ Ｓｅ | ゲノム操作のためのハイブリッド核酸配列 |
| WO2018094356A2 (en) | 2016-11-18 | 2018-05-24 | Genedit Inc. | Compositions and methods for target nucleic acid modification |
| US12029760B2 (en) * | 2017-05-04 | 2024-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for gene editing in T cells using CRISPR/Cpf1 |
| KR102907044B1 (ko) | 2017-10-02 | 2026-01-02 | 진에딧 인코포레이티드 | 변형된 cpf1 가이드 rna |
-
2018
- 2018-10-02 KR KR1020207012638A patent/KR102907044B1/ko active Active
- 2018-10-02 CA CA3077189A patent/CA3077189A1/en active Pending
- 2018-10-02 MX MX2020003339A patent/MX2020003339A/es unknown
- 2018-10-02 BR BR112020006601-0A patent/BR112020006601A2/pt unknown
- 2018-10-02 CN CN201880077637.7A patent/CN111770994B/zh active Active
- 2018-10-02 EP EP18799900.8A patent/EP3692154A1/en active Pending
- 2018-10-02 JP JP2020539688A patent/JP2020537540A/ja active Pending
- 2018-10-02 AU AU2018345683A patent/AU2018345683B2/en active Active
- 2018-10-02 US US16/753,293 patent/US12606823B2/en active Active
- 2018-10-02 KR KR1020257043505A patent/KR20260011199A/ko active Pending
- 2018-10-02 CN CN202510240123.0A patent/CN120290559A/zh active Pending
- 2018-10-02 WO PCT/US2018/054027 patent/WO2019070762A1/en not_active Ceased
- 2018-10-02 SG SG11202003083PA patent/SG11202003083PA/en unknown
- 2018-10-02 IL IL273595A patent/IL273595B2/en unknown
-
2024
- 2024-05-08 JP JP2024076160A patent/JP2024116119A/ja active Pending
-
2025
- 2025-04-11 AU AU2025202594A patent/AU2025202594A1/en active Pending
- 2025-09-10 IL IL323269A patent/IL323269A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102907044B1 (ko) | 2026-01-02 |
| AU2025202594A1 (en) | 2025-05-22 |
| CN111770994A (zh) | 2020-10-13 |
| AU2018345683B2 (en) | 2025-05-08 |
| US12606823B2 (en) | 2026-04-21 |
| SG11202003083PA (en) | 2020-05-28 |
| BR112020006601A2 (pt) | 2020-12-08 |
| AU2018345683A1 (en) | 2020-04-23 |
| IL323269A (en) | 2025-11-01 |
| US20200299689A1 (en) | 2020-09-24 |
| JP2020537540A (ja) | 2020-12-24 |
| CN120290559A (zh) | 2025-07-11 |
| AU2025202594A9 (en) | 2025-09-04 |
| IL273595B2 (en) | 2026-02-01 |
| IL273595A (en) | 2020-05-31 |
| KR20260011199A (ko) | 2026-01-22 |
| IL273595B1 (en) | 2025-10-01 |
| EP3692154A1 (en) | 2020-08-12 |
| CN111770994B (zh) | 2025-03-18 |
| JP2024116119A (ja) | 2024-08-27 |
| KR20200106485A (ko) | 2020-09-14 |
| CA3077189A1 (en) | 2019-04-11 |
| WO2019070762A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992001A1 (ru) | Композиции и способы повышения экспрессии генов | |
| CL2020003360S1 (es) | Cargador. | |
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| EP4287191A3 (en) | Hla-based methods and compositions and uses thereof | |
| MX2019008092A (es) | Metodo para acceso aleatorio y dispositivo terminal. | |
| BR112018076190A2 (pt) | ortólogos e sistemas crispr tipo vi | |
| MX2021013913A (es) | Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa. | |
| MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
| MX2020007148A (es) | Formulaciones. | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| MX2017009953A (es) | Regulacion de la expresión génica a través de la modulación mediada por un aptámero del empalme alternativo. | |
| CU24655B1 (es) | Combinación fungicida sdhi | |
| CR20180525A (es) | Producción de ácido ribonucleico libre de células | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| BR112018071519A8 (pt) | Técnicas para avaliação comparativa de estratégias de pareamento em um sistema de centro de contato | |
| CL2021002262A1 (es) | Composiciones y métodos para tratar laminopatías | |
| SA523451582B1 (ar) | Ccr8 الأجسام المضادة لـ | |
| EA201792233A1 (ru) | Способ уменьшения загрязнения поверхностей | |
| AR113812A1 (es) | Estrategias para precisión en la edición del genoma | |
| MX2021002056A (es) | Metodo para depurar especies acidas de sulfuro. | |
| BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
| MX389499B (es) | Metodos, composiciones y usos relacionados con los mismos | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| IL292004B2 (en) | Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof | |
| MX2022015284A (es) | Composiciones y metodos para la edicion del epigenoma. |